Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Licenses RNAi Technology for ALS Research from U Mass Med School

NEW YORK, June 30 - CytRx today said it has signed an exclusive, worldwide, royalty-bearing license agreement with the University of Massachusetts Medical School (UMMS) to use UMMS's RNA interference technology in the development of a treatment for amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease.

 

The approach, developed by Zuoshang Xu, associate professor of biochemistry and molecular pharmacology at UMMS, uses RNAi gene silencing to search for mutant genes that cause ALS.

 

"While several promising treatments are being developed for ALS, the specificity and power of RNAi technology could advance these efforts significantly," said Steven Kriegsman, CytRx CEO.

 

Financial details of the licensing agreement were not disclosed.

 

The agreement is part of a broad strategic alliance between CytRx and UMMS that also includes exclusive licensing agreements for the use of RNAi in the development of therapeutic products to treat obesity and type II diabetes.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.